全文获取类型
收费全文 | 2193篇 |
免费 | 749篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 16篇 |
儿科学 | 130篇 |
妇产科学 | 11篇 |
基础医学 | 18篇 |
口腔科学 | 14篇 |
临床医学 | 799篇 |
内科学 | 965篇 |
皮肤病学 | 45篇 |
神经病学 | 126篇 |
特种医学 | 18篇 |
外科学 | 183篇 |
综合类 | 4篇 |
预防医学 | 336篇 |
眼科学 | 10篇 |
药学 | 78篇 |
肿瘤学 | 210篇 |
出版年
2024年 | 20篇 |
2023年 | 149篇 |
2022年 | 87篇 |
2021年 | 97篇 |
2020年 | 196篇 |
2019年 | 57篇 |
2018年 | 202篇 |
2017年 | 203篇 |
2016年 | 205篇 |
2015年 | 196篇 |
2014年 | 218篇 |
2013年 | 220篇 |
2012年 | 71篇 |
2011年 | 60篇 |
2010年 | 146篇 |
2009年 | 231篇 |
2008年 | 67篇 |
2007年 | 34篇 |
2006年 | 46篇 |
2005年 | 57篇 |
2004年 | 35篇 |
2003年 | 33篇 |
2002年 | 19篇 |
2001年 | 32篇 |
2000年 | 36篇 |
1999年 | 39篇 |
1998年 | 33篇 |
1997年 | 25篇 |
1996年 | 27篇 |
1995年 | 28篇 |
1994年 | 16篇 |
1993年 | 15篇 |
1992年 | 8篇 |
1991年 | 7篇 |
1990年 | 7篇 |
1989年 | 6篇 |
1988年 | 5篇 |
1987年 | 9篇 |
1986年 | 4篇 |
1985年 | 5篇 |
1984年 | 2篇 |
1983年 | 6篇 |
1982年 | 2篇 |
1979年 | 1篇 |
1976年 | 1篇 |
排序方式: 共有2963条查询结果,搜索用时 218 毫秒
11.
Karissa Y. Kim PharmD CACP ; Kelly Epplen PharmD CACP ; Farzin Foruhari MD ; Hattie Alexandropoulos PharmD 《Progress in cardiovascular nursing》2006,21(2):1-4
A 79-year-old man with a history of deep vein thrombosis and pulmonary embolism received anticoagulation therapy with warfarin 5 mg daily for 8 months. He was diagnosed with osteomyelitis and underwent partial metatarsal resection of his right foot. After surgery, antibiotics were initiated including ertapenem sodium 1 g intravenously every 24 hours, vancomycin 1400 mg intravenously every 24 hours, and rifampin 300 mg by mouth twice daily. Achieving a therapeutic level of anticoagulation was difficult despite escalating doses of warfarin, because of the interaction with rifampin. A 5- to 6-fold increase in warfarin dose was prescribed to reach therapeutic international normalized ratios (INRs), but even these increases were insufficient to maintain his INR in the therapeutic range. After rifampin was discontinued, warfarin doses were gradually reduced over the next 2 months. When concurrent warfarin-rifampin therapy is necessary, vigilant monitoring is imperative and significant increases in warfarin doses are likely. 相似文献
12.
Solish Nowell MD Benohanian Antranik MD Jonathan W. Kowalski PharmD MS on Behalf of the Canadian Dermatology Study Group on Health-Related Quality of Life in Primary Axillary Hyperhidrosis 《Dermatologic surgery》2005,31(4):405-413
BACKGROUND: Patients with primary axillary hyperhidrosis experience substantial functional impairment and reduced health-related quality of life (HRQOL). Few studies have comprehensively evaluated the effects of botulinum toxin type A (BoNT-A) on these symptoms. OBJECTIVE: To prospectively assess the effects of BoNT-A on functional impairment associated with primary axillary hyperhidrosis. METHODS: Patients treated with BoNT-A 50 U per axilla at baseline were assessed 4 and 12 weeks later. Outcome measures included functional impairment as assessed by the Hyperhidrosis Disease Severity Scale and the Hyperhidrosis Impact Questionnaire and dermatology-specific HRQOL as assessed by the Dermatology Life Quality Index. RESULTS: At weeks 4 and 12 after BoNT-A treatment, 85% and 90% of patients achieved the a priori definition of treatment responder. Patients reported less occupational and emotional impairment, spent less time managing their hyperhidrosis, and had fewer difficulties in social situations. Adverse events were uncommon (5.5%), were mild, and did not require treatment. At study end, 53% of patients reported no dermatology-specific HRQOL impairment and 90% were satisfied with treatment. CONCLUSIONS: Significant, meaningful, rapid, and durable reductions in disease severity and functional impairment, as well as improvements in HRQOL, were seen following BoNT-A treatment. BoNT-A was safe and well tolerated, producing high levels of patient satisfaction. 相似文献
13.
14.
15.
Douglas Wholey PhD ; Ira Moscovice PhD ; Terry Hietpas PharmD ; Jeremy Holtzman MD MS 《The Journal of rural health》2004,20(4):304-313
The environmental context of patient safety and medical errors was explored with specific interest in rural settings. Special attention was paid to unique features of rural: healthcare organizations and their environment that relate to the patient safety issue and medical errors (including the distribution of patients, types of adverse events associated with learning, information flows, triage and transfer decisions, and culture of safety). Relevant organizational theories and strategies fo medical error reduction and prevention in rural health care settings were identified. Financial and technical assistance are needed to support the systematic collection of data from rural hospitals and other entities and to enhance relevant patient safety practices for rural America. 相似文献
16.
17.
James B. Harris MD Richard C. Ahrens MD Gary Milavetz PharmD Linda Annis Rebecca Ries BA Connie Hendricker RRT 《The Journal of allergy and clinical immunology》1990,85(6):1043-1049
Inhaled beta-agonists can produce bronchodilatation and reduce airway hyperreactivity in patients with asthma. Using these two measures, we compared inhaled bitolterol (three puffs, 1110 micrograms), albuterol (two puffs, 180 micrograms), and placebo administered by metered-dose inhaler in a blinded, crossover study of 40 subjects with chronic asthma. On each study day, subjects underwent histamine challenges at 1 1/2 hours before, and 1/2, 2, 4, 6, and 8 hours after inhaling one of the three test-drug treatments. Both drugs produced significant bronchodilatation at 30 minutes through 4 hours and significant effects on airway reactivity at 30 minutes through 2 hours (p less than 0.05). Bitolterol also produced small but significant bronchodilator effects at 6 hours and effects on airway reactivity at 4 hours (p less than 0.05). Effects of bitolterol on airway reactivity diminished significantly more slowly than effects of albuterol in subjects with baseline provocative concentration causing a 20% fall in FEV1 greater than or equal to 1.0 mg/ml of histamine (half-life of biologic effect 1.37 versus 0.92 hours; p less than 0.05) but not in subjects with baseline provocative concentration causing a 20% fall in FEV1 less than or equal to 1.0 mg/ml (half-life of biologic effect of 1.01 versus 1.00 hours; p greater than 0.05). 相似文献
18.
19.
Dane Christina Daoud MD Elena M. S. Cartagena MD MSc Katherine J. P. Schwenger RD PhD Nicha Somlaw MD Leah Gramlich MD Scott Whittaker MD David Armstrong MD Brian Jurewitsch PharmD Matreyi Raman MD Donald R. Duerksen MD James D. McHattie MD Johane P. Allard MD 《JPEN. Journal of parenteral and enteral nutrition》2022,46(2):348-356
20.
Hamed Nikoupour MD Peyman Arasteh MD MPH Alireza Shamsaeefar MD Fardin Ghanbari MD Arash Boorboor MD Ali Mosa Jafar Almayali MD Mojtaba Shafiekhani PharmD Ph.D Pirouz Samidoust MD Reza Shahriarirad MD Alireza Shojazadeh MD Keivan Ranjbar MD Mohammad Hasan Darabi MD Sina Tangestanipour MD Seyed Morteza Hosseini MD Leila Zahiri MD Saman Nikeghbalian MD 《JPEN. Journal of parenteral and enteral nutrition》2022,46(4):946-957